Symbole: LLY

Eli Lilly

Pharma Santé Fabricants de médicaments - généralistes

Prix 1417.54

Reco Acheter Potentiel 74 Risque 33 Mis à jour 2026-10-31

Site officiel

Impact de la prévision

positif

Objectif +12.9% atteinte de l’objectif 88.6%

Réaction D5 en attente · D10 en attente récent confirmé · confiance du marché

Impact Potentiel +6 · Risque -3 valide jusqu’au 2026-11-29

Suivre dans le portefeuille

Graphique des prix

Recommandation IA Prévision d’analyste Événement calendrier Signal positif Signal négatif Neutre / mise à jour Conserver / informatif B Mon achat S Ma vente

Description

Entreprise et modèle économique

Eli Lilly est une entreprise mondiale de santé qui se concentre sur la découverte, le développement et la commercialisation de produits pharmaceutiques. Ses produits phares incluent des traitements pour le diabète, l'oncologie, l'immunologie et les maladies neurodégénératives. Les principaux segments d'activité comprennent les soins du diabète, l'oncologie et les neurosciences, avec des revenus significatifs générés par les produits à base d'insuline et les thérapies contre le cancer. L'entreprise est reconnue pour son pipeline de médicaments innovants et sa forte présence sur le marché de la santé.

Profil d’investissement

L'action d'Eli Lilly est positionnée comme un investissement équilibré, attirant les investisseurs à la recherche d'une croissance modérée et d'un revenu grâce aux dividendes. L'entreprise affiche une croissance stable des revenus et un rendement des dividendes constant, ce qui la rend adaptée à ceux qui recherchent un mélange d'appréciation du capital et de revenu. Sa présence établie sur le marché et son développement de produits en cours contribuent à un profil de risque-rendement favorable.

Catégorie: Pharma Secteur: Santé Industrie: Fabricants de médicaments - généralistes Style d’investissement: Croissance Horizon: Long terme Type d’entreprise: Blue chip Type d’entreprise: Leader du marché Expérience: Basique

Métriques fondamentales (expérimental) Mis à jour: 2026-10-31

BPA (TTM) — bénéfice par action des 12 derniers mois, $: 29.89
Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires: 16.0%
Surprise BPA: 30.9%
Volatilité 20 j: 2.2%
Rendement du dividende: 0.5%
dernière date ex-dividende: 2026-08-14

Changements de recommandation IA

Date	Avant	Après	Raison
2026-10-11	Conserver	Acheter	Strong fundamentals and positive momentum support growth outlook.
2026-10-03	Acheter	Conserver	Strong fundamentals but mixed momentum signals.
2026-09-15	Conserver	Acheter	Strong fundamentals, but recent negative momentum concerns.
2026-09-06	Acheter	Conserver	Mixed performance; cautious due to high risk factors.
2026-08-06	Conserver	Acheter	Strong fundamentals and positive momentum support growth outlook.
2026-07-31	Acheter	Conserver	Weak momentum and high risk; cautious approach advised.
2026-05-18	Conserver	Acheter	Strong fundamentals and positive short-term momentum.
2026-05-10	Acheter	Conserver	Weak momentum and high risk; mixed analyst signals.
2026-05-08	—	Acheter	Solid fundamentals but mixed momentum signals.
2026-05-08	Acheter	Acheter	Компания показывает стабильный рост выручки и положительные сюрпризы по EPS, однако недавние колебания цен и негативная динамика на более длительных сроках вызывают осторожность.
2026-04-29	Conserver	Acheter	Компания Eli Lilly демонстрирует стабильный рост выручки и положительный сюрприз по прибыли, однако недавние колебания цен акций и снижение на более длительных горизонтах вызывают опасения. Рекомендуется удерживать акции
2026-04-17	Acheter	Conserver	Компания Eli Lilly демонстрирует стабильный рост выручки и положительный сюрприз по EPS, однако недавние колебания цен акций и снижение на коротких временных интервалах могут указывать на повышенные риски.
2026-04-09	Conserver	Acheter	Компания Eli Lilly демонстрирует стабильный рост выручки и положительные результаты по EPS, что указывает на сильные финансовые показатели. Несмотря на недавние колебания цен, долгосрочные тренды и позитивные прогнозы де
2026-03-22	Acheter	Conserver	Компания Eli Lilly демонстрирует сильный рост выручки и положительный сюрприз по прибыли, однако недавнее снижение цен акций и высокая волатильность могут указывать на риски в краткосрочной перспективе.
2026-02-06	Conserver	Acheter	Компания Eli Lilly демонстрирует сильный рост за последние 120 дней, однако недавнее падение на 7.79% может указывать на краткосрочные риски. Рекомендуется удерживать акции до более ясной картины.
2026-01-29	Acheter	Conserver	Компания Eli Lilly демонстрирует сильный рост за последние 60 и 120 дней, однако недавние колебания цен указывают на возможную волатильность. Рекомендуется удерживать акции до более ясных сигналов о дальнейшем движении.

Prévisions des analystes

Date	Analyste	Action	Objectif	Prix alors
2026-10-30	RBC Capital	Objectif relevé	— → 1600	1425.335
2026-10-30	Argus Research	Objectif relevé	— → 1550	1373
2026-10-30	UBS	Objectif relevé	— → 1625	1373
2026-10-30	BMO Capital	Objectif relevé	— → 1650	1373
2026-10-30	KeyBanc	Objectif relevé	— → 1497	1373
2026-10-30	Wells Fargo	Objectif relevé	— → 1500	1373
2026-10-30	Truist Financial	Objectif relevé	— → 1612	1373
2026-10-26	Bernstein	Objectif relevé	1385 → 1450	1273.46
2026-10-21	Leerink Partners	Objectif relevé	1309 → 1316	1265.92
2026-10-20	Goldman Sachs	Objectif relevé	1371 → 1413	1300.46
2026-10-08	Cantor Fitzgerald	Objectif relevé	1410 → 1440	1188.72
2026-10-07	Morgan Stanley	Objectif relevé	1419 → 1430	1184.475
2026-09-18	Guggenheim	Objectif relevé	— → 1284	1152.13
2026-09-15	Berenberg Bank	Mettre à jour	— → 1400	1137.75
2026-09-10	HSBC	Objectif relevé	850 → 940	1124.16
2026-08-07	UBS	Objectif relevé	1370 → 1376	1177.33
2026-08-06	Cantor Fitzgerald	Objectif relevé	1350 → 1410	1181
2026-08-06	Morgan Stanley	Objectif relevé	1347 → 1419	1169.86
2026-08-06	Wells Fargo	Objectif relevé	— → 1330	1169.86
2026-08-06	BMO Capital	Objectif relevé	— → 1400	1169.86
2026-07-14	Bernstein	Objectif relevé	— → 1385	1185.08
2026-07-13	UBS	Objectif relevé	1250 → 1425	1189.91003
2026-07-13	Guggenheim	Objectif relevé	— → 1273	1188.58
2026-07-09	UBS	Objectif relevé	1281 → 1370	1222.125
2026-07-08	Truist Financial	Objectif relevé	— → 1370	1227.07
2026-07-08	RBC Capital	Objectif relevé	1250 → 1500	1229.21997
2026-07-08	Morgan Stanley	Objectif relevé	1344 → 1347	1235.56
2026-07-06	Cantor Fitzgerald	Objectif relevé	— → 1350	1210.5
2026-06-25	Leerink Partners	Objectif relevé	1119 → 1232	1117.26
2026-06-22	Berenberg Bank	Objectif relevé	1050 → 1135	1111.67
2026-06-09	Jefferies	Objectif relevé	1330 → 1350	1143.35
2026-05-26	HSBC	Objectif relevé	— → 1251	1065
2026-05-26	Leerink Partners	Mettre à jour	— → 1119	1065
2026-05-21	Wolfe Research	Objectif relevé	1325 → 1350	1037.82007
2026-05-05	Barclays	Objectif relevé	1350 → 1400	967.93
2026-05-01	Morgan Stanley	Objectif relevé	1327 → 1344	961.555
2026-05-01	Cantor Fitzgerald	Objectif relevé	1205 → 1230	970.675
2026-04-10	Morgan Stanley	Objectif relevé	1313 → 1327	939.31
2026-03-13	Jefferies	Mettre à jour	— → 1300	1000.78003
2026-03-06	Deutsche Bank	Mettre à jour	— → 1285	990.31
2026-03-05	Morgan Stanley	Mettre à jour	— → 1313	972.5

Actualités Page 6 sur 7

The Pharmaceutical Industry Embraces Space: Drug Development in Low Earth Orbit Gains Momentum

06/09/2026, 12:32 AM growth pharma space SpaceX Merck Redwire Eli Lilly

The shift of pharmaceutical development to lower Earth orbit represents a significant evolution in the space economy, with the potential to enhance drug formulation and delivery methods. This trend could disrupt traditional pharmaceutical practices and create new investment opportunities as the space economy is projected to exceed $1 trillion by 2040.

Jim Cramer Maintains Position in Eli Lilly (LLY) Amid Strong Obesity Drug Pipeline

06/08/2026, 12:35 PM business review healthcare Eli Lilly

Eli Lilly's stock continues to rise, driven by promising data on its obesity drug retatrutide, prompting analysts and investors to maintain their positions despite the stock's significant gains.

Analysts expect Johnson & Johnson (JNJ) to show potential for breakout following Eli Lilly’s (LLY) recent all-time highs

06/08/2026, 11:35 AM investing forecast Analysts: analysts pharma healthcare Johnson & Johnson Eli Lilly

Pharmaceutical stocks are gaining momentum, with Eli Lilly leading the charge and reaching all-time highs, indicating a potential for broader sector strength that could benefit other major companies like Johnson & Johnson.

Novo Nordisk and Eli Lilly Compete for Dominance in the GLP-1 Pill Market Ahead of Medicare Coverage

06/08/2026, 10:48 AM business review healthcare Novo Nordisk Eli Lilly

Novo Nordisk and Eli Lilly are intensifying their competition in the GLP-1 pill market as they prepare for Medicare coverage, which could significantly increase access to their obesity treatments. Both companies are focusing on marketing strategies to appeal to seniors, who will soon be able to access these medications at a reduced cost.

Stock Market Experiences Significant Decline Following Strong Jobs Report and Disappointing Earnings from Tech Companies

06/06/2026, 10:32 AM economy review tech semiconductors SpaceX Wells Fargo Intel Broadcom Eli Lilly

Last week's stock market experienced a significant downturn, primarily driven by disappointing earnings from major tech companies and a strong jobs report that diminished expectations for a Federal Reserve interest rate cut. This shift has raised concerns about the sustainability of recent market highs and the potential impact of increased stock supply from upcoming IPOs.

Cramer Highlights Buying Opportunity in AI Stocks Amid Market Cooling

06/05/2026, 10:33 AM economy review ai tech CrowdStrike Holdings SpaceX Cardinal Health Intel Johnson & Johnson Apple Broadcom Eli Lilly

The recent decline in stock prices, particularly in the tech sector, presents a potential buying opportunity for investors, especially in chip stocks and AI-related companies, according to Jim Cramer.

Dow Jones Industrial Average Hits Record High as Health-Care Stocks Lead Market Gains

06/05/2026, 05:34 AM business review healthcare UnitedHealth Humana Centene Eli Lilly

Despite a decline in chip stocks, the U.S. stock market saw significant gains, with the Dow Jones Industrial Average reaching a new record, driven largely by strong performance in the health-care sector.

Jim Cramer Suggests Trimming Goldman Sachs (GS) and Wells Fargo (WFC) Positions for Different Reasons

06/04/2026, 09:31 AM economy review finance CrowdStrike Holdings Goldman Sachs Wells Fargo Johnson & Johnson Eli Lilly

Investors are witnessing a sector rotation from AI hardware to healthcare and financials, with notable movements in stocks like Goldman Sachs and CrowdStrike, indicating shifting market dynamics.

Eli Lilly’s Business Development Head Jacob Van Naarden Signals Increased M&A Activity as Company Pursues New Opportunities

06/03/2026, 04:33 AM business announcement healthcare Eli Lilly

Eli Lilly is leveraging its significant financial strength, driven by its successful weight loss drugs, to pursue an aggressive acquisition strategy aimed at diversifying its drug pipeline and expanding into new therapeutic areas. This shift marks a notable change in Lilly's approach to dealmaking as it seeks to capitalize on its recent growth.

Analysts JPMorgan recommend top stocks for June, including Viasat (VSAT) and Eli Lilly (LLY)

06/02/2026, 08:31 AM investing recommendation Analysts: analysts, JPMorgan software telecom Viasat Eli Lilly

JPMorgan's updated list of top investment ideas for June highlights strong performance in U.S. stocks, particularly in technology, and includes new recommendations such as Viasat, which has seen significant growth despite recent volatility.